US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bio Blast Pharma

11.50

0.0000

Volume:- -

Turnover:- -

Market Cap:4.83M

PE:-1.44

High:11.50

Open:11.50

Low:11.50

Close:11.50

52wk High:30.00

52wk Low:6.19

Shares:419.89K

Float Shares:255.87K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.9626

EPS(LYR):-14.3528

ROE:--

ROA:--

PB:3.10

PE(LYR):-0.80

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Bio Blast Pharma

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.bioblast-pharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Bio Blast Pharma Ltd., a clinical development-stage biopharmaceutical company, focuses on the identification, licensing, acquisition, development, and commercialization clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The companys drug candidates under clinical or preclinical development includes Trehalose 90mg/mL IV solution, a mutant protein stabilizer and autophagy enhancer used for protein-based drugs that are administered intravenously to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. Its drug candidates under clinical or preclinical development also comprise BB-FA, a mitochondrial protein replacement platform to treat various diseases caused by mutations in genes associated with mitochondrial-related proteins, such as Friedreichs ataxia; and BBrm-02, an azithromycin in a formulation suitable for intrathecal delivery intended to treat spinal muscular atrophy, and other neurodegenerative and neurodevelopmental diseases. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in New Haven, Connecticut.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORPN/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORPN\",,,,,undefined,":{"symbol":"ORPN","market":"US","secType":"STK","nameCN":"Bio Blast Pharma","latestPrice":11.5,"timestamp":1553543999999,"preClose":11.5,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":255869,"shares":419889,"eps":-7.962627,"marketStatus":"Market Closed","change":0,"latestTime":"03-25 15:59:59 EDT","open":11.5,"high":11.5,"low":11.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.962627,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"symbolChange":{"newSymbol":"ENLV","executeDate":"2019-03-26"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":11.5,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORPN\",,,,,undefined,":{"symbol":"ORPN","floatShares":255869,"roa":"--","roe":"--","lyrEps":-14.35283,"shares":419889,"dividePrice":0,"high":11.5,"amplitude":0,"preClose":11.5,"low":11.5,"week52Low":6.1904,"pbRate":"3.10","week52High":30,"institutionHeld":0,"latestPrice":11.5,"eps":-7.962627,"divideRate":0,"volume":0,"delay":0,"ttmEps":-7.962627,"open":11.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORPN\",params:#limit:5,,,undefined,":[{"date":"2019-03-26","symbol":"ORPN","newSymbol":"ENLV","type":"symbolChange","dateTimestamp":1553572800000},{"date":"2019-03-06","symbol":"ORPN","type":"split","dateTimestamp":1551848400000,"forFactor":8,"toFactor":1},{"market":"US","date":"2017-11-02","symbol":"ORPN","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"","actualEps":-0.32},{"date":"2017-09-25","symbol":"ORPN","type":"split","dateTimestamp":1506312000000,"forFactor":5,"toFactor":1},{"market":"US","date":"2017-08-04","symbol":"ORPN","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1501819200000,"reportTimeType":"","actualEps":-0.1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORPN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.bioblast-pharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bio Blast Pharma Ltd., a clinical development-stage biopharmaceutical company, focuses on the identification, licensing, acquisition, development, and commercialization clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The companys drug candidates under clinical or preclinical development includes Trehalose 90mg/mL IV solution, a mutant protein stabilizer and autophagy enhancer used for protein-based drugs that are administered intravenously to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. Its drug candidates under clinical or preclinical development also comprise BB-FA, a mitochondrial protein replacement platform to treat various diseases caused by mutations in genes associated with mitochondrial-related proteins, such as Friedreichs ataxia; and BBrm-02, an azithromycin in a formulation suitable for intrathecal delivery intended to treat spinal muscular atrophy, and other neurodegenerative and neurodevelopmental diseases. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in New Haven, Connecticut.","exchange":"NASDAQ","name":"Bio Blast Pharma","nameEN":"Bio Blast Pharma"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ORPN\",market:\"US\",,,undefined,":null}}